Wednesday, May 26, 2010 4:08:03 PM
>>If Eva has some results on June 6th, what does that say about the many many months we have been waiting for results on prior tests? <<
Ovi, If you were attentive you would have clearly seen that the Eva deal was completely different than the one's with the other institutions.
Eva is 'Dengue'. Reviewing the preliminary test protocols already available from NNVC, she jumped right on it. Did the tests. The results are done and being broken down in a form where they can be understood by a non scientific reader. Then that translation has to be resent and agreed by all parties that it is indeed accurate. From there, the main portions of the text are picked and and used to form the Press Release.
With all the other Institutions they were a 'freebee' to NNVC outside of the actutal formulation. As a 'freebee' quess where they get in line compared to the paying customers?
That's the way I see it.
-Bunny-
Ovi, If you were attentive you would have clearly seen that the Eva deal was completely different than the one's with the other institutions.
Eva is 'Dengue'. Reviewing the preliminary test protocols already available from NNVC, she jumped right on it. Did the tests. The results are done and being broken down in a form where they can be understood by a non scientific reader. Then that translation has to be resent and agreed by all parties that it is indeed accurate. From there, the main portions of the text are picked and and used to form the Press Release.
With all the other Institutions they were a 'freebee' to NNVC outside of the actutal formulation. As a 'freebee' quess where they get in line compared to the paying customers?
That's the way I see it.
-Bunny-
Recent NNVC News
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
